No Detail Found!

Analysis of cardio-cerebrovascular adverse events in patients with brain metastasis from lung cancer treated with antiangiogenic drugs

Author(s)
Yuqing Zhang MA Department of Oncology, Tangshan Gongren Hospital affiliated to North China University of Science and Technology, Tangshan, Hebei Province, China
Haitao Zhang Department of Infection, Tangshan Central Hospital,Tangshan, Hebei Province,China
Wenguang Song Department of Oncology, Tangshan Gongren Hospital, Tangshan, Hebei Province, China
Abstract
To observe the occurrence of cardio-cerebrovascular adverse events in patients with brain metastases from lung cancer treated with antiangiogenic drugs. A total of 182 patients with brain metastases from lung cancer were selected as the research objects. They were divided into patients receiving antiangiogenic drugs and those not receiving antiangiogenic drugs. The incidence of cardio-cerebrovascular adverse events was observed. The incidence of low-grade hypertension, cerebral haemorrhage, cerebrovascular accident, cerebrovascular arrhythmia and other cardiocerebrovascular adverse events in patients with brain metastases from lung cancer after receiving antiangiogenic therapy was higher than in the group that did not receive anti-vascular therapy (P0.05). Head radiotherapy did not increase the rate of cardiocerebrovascular adverse events among patients treated with antiangiogenic drugs (P< 0.05), and the incidence of adverse events was lowest in the endost group combined with radiotherapy. The incidence of cardio-cerebrovascular adverse events in the combined gemcitabine + platinum (GP) and irinotecan + platinum (IP) regimen group was higher than that in the other combined chemotherapy regimen groups. Treatment of brain metastases from lung cancer using antiangiogenic drugs increases the incidence of low-grade cardio-cerebrovascular adverse events, but these drugs are safe and controllable and are worthy of clinical application.
Publication Details
Page(s) 77-84
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 35, Issue: 1, Year: 2022

Request the full text from PASTIC

Keywords
Lung Cancer, Brain metastasis, Adverse Drug Reaction, cardio-Cerebrovascular, Antiangiogenic therapy
References
Bernhardt D,Adeberg S,Bozorgmehr F,Opfermann N,Hoerner-Rieber J,Konig L,Kappes J,Thomas M,Herth F,Heußel CP,Warth A,Debus J,Steins M,Rieken S M .2017 .Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy. J. Neurooncol., 134(1) : 205-212.
Besse B,Le Moulec S,Mazieres J,Senellart H,Barlesi F,Chouaid C,Dansin E,Berard H,Falchero L,Gervais R,Robinet G,Ruppert A-M R,Léna H,Clément-Duchêne C,Quantin X,Souquet PJ,Trédaniel J,Moro-Sibilot D,Pérol M,Madroszyk AC,Soria JC .1896 .Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study. Clin. Cancer Res., 21(8) : .
Braganca KCD,Janjigian YY,Azzoli CG,Kris MG,Pietanza MC,Nolan CP,Omuro AM,Holodny AI,Lassman AB .2010 .Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J. Neurooncol., 100(3) : 443-447.
Cheng JD,Chai LX,Zhao ZP,Hao YY,Li S YY .2020 .Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor. Cancer Manag. Res., 12 : 5641-5650.
Dansin E,Cinieri S,Garrido P,Griesinger F,Isla D,Koehler M,Kohlhaeufl M M .2012 .MO19390 (SAiL): Bleeding events in a phase IV study of firstline bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. Lung Cancer, 76(3) : 373-379.
De Graaf JC,Banga JD,Moncada S,Palmer RM,Groot P G,Sixma JJ .1992 .Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation, 85(6) : 2284-2290.
Fenske DC,Price GL,Hess LM,John WJ,Kim ES .2017 .Systematic Review of Brain Metastases in Patients With Non-Small-Cell Lung Cancer in the United States. Clin. Lung Cancer, 18(6) : 607-614.
Ferrara N .2004 .Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev, 25(4) : 581-611.
Fox BD,Cheung VJ,Patel AJ,Suki D,Rao G .2011 .Epidemiology of metastatic brain tumors. Neurosurg. Clin. N. Am., 22(1) : 1-6.
Ian Z .2001 .Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am. J. Physiol Cell Physiol, 280(6) : C1375.
Ling Y,Yang Y,Lu N,You QD,Wang S,Gao Y,Chen Y,Guo QL .2007 .Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem. Biophys. Res. Comm., 361(1) : 79-84.
Lukas RV,Kumthekar P,Rizvi S,Salgia R .2016 .Systemic therapies in the treatment of non-small-cell lung cancer brain metastases. Future Oncol., : 1045-1058.
Lu X,Kang Y.,Hypoxia Y.,Hypoxia-Inducible Factors . .. Clin. Cancer Res., 16(24) : 5928-35.
Lynch TJ,Spigel DR,Brahmer J,Fischbach N,Garst J,Jahanzeb M,Kumar P,Vidaver R M A J,Fish S,Flick ED,Leon L,Hazard SJ,Kosty MP . .Safety and Effectiveness of Bevacizumab-Containing Treatment for Non-SmallCell Lung Cancer: Final Results of the ARIES Observational Cohort Study. J. Thorac. Oncol, 9(9) : 1332-1339.
Masuda C,Sugimoto M,Wakita D,Monnai M,Ishimaru C,Nakamura R,Kinoshita M,Yorozu K,Kurasawa M,Kondoh O,Yamamoto K O .2020 .Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model. Clin. Exp, 37(1) : 199-207.
Peng L,Wang Y,Fei S,Wei C H,Tong F,Wu G,Ma H,Dong XR .2020 .The effect of combining Endostar with radiotherapy on blood vessels, tumor-associated macrophages, and T cells in brain metastases of Lewis lung cancer. Transl. Lung Cancer Res., 9(3) : 745-760.
Qin TT,Liu ZJ,Wang J,Xia J L,Liu S C,Jia Y N,Liu H L and Li K Y N .2020 .Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling. Cancer Biol. Med, 17 : 753-767.
Reck M,Von Pawel J,Zatloukal P,Ramlau R,Gorbounova V,Hirsh V,Leighl N,Mezger J,Archer V,Moore N,Manegold C .2010 .Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: Results from a randomised phase III trial (AVAiL). , 21(9) : 1804-1809.
Reck ,Clin .2009 .Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. , 27(8) : 1227.
Rini BI,Sosman JA,Motzer RJ .2005 .Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: Biology, clinical results and future development. BJU Int, 96(3) : 286-90.
Sandler A,Hirsh V,Reck M,Pawel JV,Akerley W,Johnson DH .2012 .An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases. Lung Cancer, 78(1) : 1-7.
Xu HF,Zhao GP,Yang JJ,Wen XP .2019 .Advances in toxicity risk analysis and effective treatments for targeted antiangiogenic drugs. Int. J. Clin. Exp. Med, 12 : 12020-12027.
Yao SK,Ober JC,Krishnaswami A,Ferguson J J,Anderson HV,Golino P,Buja LM,Willerson JT .1992 .Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation, 86(4) : 1302-1309.
Yongli Z,Jigang D,Bo L,Maojiang L,Yan C,Xiaoxiao L C .2017 .The value analysis of blood brain barrier permeability in the treatment of multiple brain metastases patients with non-small cell lung cancer. J. Mod. Oncol., 14 : 2238-2242.
0

Citations

0

Downloads

117

Views